Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

138.09 +0.55 (+0.40%)
Official Closing Price Updated: 7:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
2 Market-Beating Stocks to Buy in 2023 and Hold for 10 Years
These two healthcare giants defied the bear market last year. 
Via The Motley Fool
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies
BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) may have had a successful year of novel drug development. 
Via Benzinga
3 Drug Stocks With Promising Pipelines for 2023
These 3 drug stocks with promising pipelines are in position to reward investors in 2023 due to multiple factors. 
Via InvestorPlace
$100 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Analyst Views Novo Nordisk's Upcoming Obesity Drug Data To Lay Grounds For Eli Lilly's Tirzepatide
Cantor Fitzgerald published around 40-page deep dive ahead of Novo Nordisk A/S's (NYSE: NVO) SELECT CV outcomes study, which is guided to complete in ~mid-2023.  
Via Benzinga
Aeterna Zentaris Shelves Early-Stage Vaccine Programs, Including COVID-19
 
Via Benzinga
2 Top Biotech Stocks Defying the Bear Market
Some stocks are hitting new highs. 
Via The Motley Fool
2 Stocks That Could Be Red-Hot Buys in 2023
These stocks have already begun to rally over the past few months. 
Via The Motley Fool
How Novo Nordisk Just Expanded Its Diabetes Lead Over Pfizer, Eli Lilly
Others will have a harder time catching up with Novo Nordisk's oral GLP-1 drug. 
Via Investor's Business Daily
EXL Announces Appointment of Andreas Fibig to Board of Directors
From ExlService Holdings, Inc.
Via Globe NewsWire
Sharps Technology Is Injecting A Better Solution Into The Healthcare Syringe Industry
Medical device company Sharps Technology, Inc. (NASDAQ: STSS) is closing out a successful year after its April initial public offering (IPO) on the NASDAQ market. The company focuses on the development... 
Via Benzinga
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
Via Investor's Business Daily
Global Drug Delivery Systems Market Size Projected to Reach $71.75 Billion By 2029
EQNX::TICKER_START (NASDAQ:STSS),(NYSE:BDX),(NYSE:CAH),(NYSE:NVO),(OTCPK:TRUMY),(NASDAQ:STSSW) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Jim Cramer Says Avoid This Stock: 'Too Expensive'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Blackline, Inc. (NASDAQ: BL) was an enterprise software company that was losing money. 
Via Benzinga
Could Eli Lilly Stock Help You Become a Millionaire?
Over the past 10 years, when including its dividend, Eli Lilly's total return has amounted to an incredible 843%. 
Via The Motley Fool
How TikTok Could Help This Healthcare Stock Take Off
Novo Nordisk underestimated demand in 2022, but it's vowing not to make the same mistake this year. 
Via The Motley Fool
The Battles Brewing That Could Stoke Already Red-Hot Eli Lilly Stock
Investors are closely watching two key spaces that could spark Lilly stock. 
Via Investor's Business Daily
2 Market-Beating Stocks to Buy in 2023 and Hold Forever
For these companies' shareholders, it may be tempting to take profits right now. But both stocks can keep growing for a while. 
Via The Motley Fool
Lose Weight, Grow Your Portfolio
Novo Nordisk is set to become a major force in the weight loss market, thanks to its drug, Wegovy. 
Via Talk Markets
Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says
 
Via Benzinga
2 Smartest Tech Stocks to Buy in 2022 and Beyond
The tech space is still bursting with opportunities for long-term investors. 
Via The Motley Fool
Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
Eli Lilly & Co may be struggling with supply-side issues but new partnerships and a healthy dividend are helping to keep up their momentum 
Via MarketBeat
7 Hot Stocks to Book Profits In Before 2023
With major macroeconomic headwinds appearing on the horizon, it’s time for investors to consider the hot stocks to book profits in. 
Via InvestorPlace
Pfizer, Novartis Are Among Overbought Healthcare Stocks: Are They Worth A Look?
The most overbought stocks in the healthcare sector presents an opportunity to go short on these overvalued companies. Here’s the latest list of major overbought players in this sector, with an RSI... 
Via Benzinga
The Bullish Call Eli Lilly Made For Its Next-Gen Obesity Drug, A Rival To Novo, Amgen
All eyes are on tirzepatide, but its next-generation weight-loss shot could be even better. 
Via Investor's Business Daily
Why Jim Cramer Can't Recommend Investing In Carl Icahn's Company
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Koninklijke Philips NV (NYSE: PHG) is "just not a well-enough run company." He added Danaher Corporation (NYSE: DHR) is the 
Via Benzinga
Battered FTX's CEO Sam Bankman-Fried Arrested, Elon Musk's SpaceX Mammoth Valuation Of $140B, China Weighs Over $143B In Semiconductor Push: Top Stories Tuesday, Dec. 13
Benzinga Sam Bankman-Fried Arrested In The Bahamas 
Via Benzinga
After US Launch Bottlenecks, Novo Nordisk Pushes European Rollout For Wegovy In 2023
Novo Nordisk A/S (NYSE: NVO) will roll out its obesity treatment, Wegovy (semaglutide), in Europe in 2023 to ensure it has enough supply. 
Via Benzinga
Our 7 Top Biotech Stock Picks for 2023
Following the devastation of Covid-19, there’s greater interest toward medical innovations, thus bolstering biotech stock picks for 2023. 
Via InvestorPlace
How An Eli Lilly Decision Could Light Up The Red-Hot Obesity Landscape — Again
Eli Lilly is expected to make a key decision for a next-generation obesity drug. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.